Clinical Trial Detail

NCT ID NCT02269670
Title Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Emory University
Indications

Her2-receptor negative breast cancer

Therapies

Tamoxifen

Everolimus

Megestrol acetate

Letrozole

Fulvestrant

Anastrozole

Age Groups: adult

Additional content available in CKB BOOST